MarketCap
Facebook
X
Telegram
IMV Retained Earnings | IMV
Retained earnings — this is the portion of a company’s net profit that has not been distributed to shareholders as dividends but remains at the company’s disposal for future use. It is also referred to as retained income or accumulated earnings.Possible uses include
- reinvestment in development (R&D, equipment, marketing)
- debt repayment
- acquisition of other companies
- creation of reserves for the future
A high level of retained earnings indicates that the company is in a growth phase, accumulating capital and prioritizing reinvestment over dividend payouts. Conversely, low or negative retained earnings may suggest either a generous dividend policy, in which all profits are distributed to shareholders, or ongoing losses that reduce the overall financial result.
The presence of retained earnings does not indicate that the company has available cash — it is solely an accounting figure reflecting the accumulated portion of net profit remaining after dividends have been paid. Therefore, it is important for investors to analyze not only the amount of retained earnings, but also how effectively it is used to develop the business, reduce debt, or build financial stability.
Annual Retained Earnings IMV
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| - | -155 M | -155 M | -120 M | -92.3 M | -70.8 M | -58.8 M | -49.9 M | -41.1 M | -34.6 M | -29.9 M | -23.5 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -23.5 M | -155 M | -75.5 M |
Quarterly Retained Earnings IMV
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | -155 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -155 M | -155 M | -155 M |
Retained Earnings of other stocks in the Biotechnology industry
| Issuer | Retained Earnings | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AbbVie
ABBV
|
-15.5 B | $ 263.04 | 0.49 % | $ 465 B |  USA |
 |
AbCellera Biologics
ABCL
|
-29.5 M | $ 11.41 | 2.15 % | $ 3.41 B |  Canada |
 |
Фармсинтез
LIFE
|
-3.54 B | - | - | - |  Russia |
 |
Aclaris Therapeutics
ACRS
|
-968 M | $ 5.53 | 6.02 % | $ 678 M | USA |
 |
ADC Therapeutics SA
ADCT
|
-1.64 B | $ 1.09 | 3.74 % | $ 139 M |  Schweiz |
 |
Amryt Pharma plc
AMYT
|
-233 M | - | - | $ 621 M |  Britain |
 |
Evelo Biosciences
EVLO
|
-529 M | - | -14.46 % | $ 27.9 M | USA |
 |
Allakos
ALLK
|
-1.23 B | - | - | $ 28.6 M | USA |
 |
Checkmate Pharmaceuticals
CMPI
|
-201 M | - | - | $ 231 M | USA |
 |
Clovis Oncology
CLVS
|
-2.88 B | - | -7.23 % | $ 13 M | USA |
 |
Chimerix
CMRX
|
-884 M | - | - | $ 756 M | USA |
 |
Concert Pharmaceuticals
CNCE
|
-349 M | - | - | $ 401 M | USA |
 |
ADMA Biologics
ADMA
|
-162 M | $ 8.61 | 0.16 % | $ 2.05 B | USA |
 |
Eiger BioPharmaceuticals
EIGR
|
-512 M | - | -9.21 % | $ 2.55 M | USA |
|
89bio
ETNB
|
-825 M | - | - | $ 1.55 B | USA |
 |
Freeline Therapeutics Holdings plc
FRLN
|
-445 M | - | - | $ 384 M | Britain |
 |
Fusion Pharmaceuticals
FUSN
|
-377 M | - | - | $ 1.41 B | Canada |
 |
Guardion Health Sciences
GHSI
|
-93.6 M | - | -0.31 % | $ 3.64 M | USA |
 |
Genocea Biosciences
GNCA
|
-408 M | - | -15.0 % | $ 3.04 M | USA |
 |
Gritstone Oncology
GRTS
|
-660 M | - | 0.42 % | $ 213 M | USA |
 |
G1 Therapeutics
GTHX
|
-780 M | - | - | $ 370 M | USA |
 |
Harpoon Therapeutics
HARP
|
-353 M | - | - | $ 763 M | USA |
 |
Humanigen
HGEN
|
-682 M | - | -81.12 % | $ 4.28 M | USA |
 |
HOOKIPA Pharma
HOOK
|
-413 M | - | -6.92 % | $ 79.4 M | USA |
 |
Intercept Pharmaceuticals
ICPT
|
-2.14 B | - | - | $ 643 M | USA |
 |
IGM Biosciences
IGMS
|
-1.02 B | - | - | $ 76.9 M | USA |
 |
Intra-Cellular Therapies
ITCI
|
-1.69 B | - | - | $ 13.6 B | USA |
 |
Kinnate Biopharma
KNTE
|
-372 M | - | - | $ 123 M | USA |
 |
Chinook Therapeutics
KDNY
|
-420 M | - | - | $ 2.6 B | USA |
 |
Kaleido Biosciences
KLDO
|
-364 M | - | -3.69 % | $ 12.4 M | USA |
 |
Kronos Bio
KRON
|
-595 M | - | 1.49 % | $ 50.8 M | USA |
 |
Karuna Therapeutics
KRTX
|
-998 M | - | - | $ 12.2 B | USA |
 |
Landos Biopharma
LABP
|
-155 M | - | 0.58 % | $ 144 M | USA |
 |
La Jolla Pharmaceutical Company
LJPC
|
-1.06 B | - | - | $ 154 M | USA |
 |
LogicBio Therapeutics
LOGC
|
-140 M | - | - | $ 229 M | USA |
 |
Lumos Pharma
LUMO
|
-162 M | - | - | $ 35.3 M | USA |
 |
Merrimack Pharmaceuticals
MACK
|
-549 M | - | - | $ 216 M | USA |
 |
Stealth BioTherapeutics Corp
MITO
|
-608 M | - | - | $ 23.9 M | USA |
 |
Mirati Therapeutics
MRTX
|
-2.45 B | - | - | $ 3.3 B | USA |
 |
NexImmune
NEXI
|
-223 M | - | 70.13 % | $ 4.12 M | USA |
 |
9 Meters Biopharma
NMTR
|
-213 M | - | -42.97 % | $ 1.05 M | USA |
 |
InVivo Therapeutics Holdings Corp.
NVIV
|
-249 M | - | -37.48 % | $ 476 K | USA |
 |
Nymox Pharmaceutical Corporation
NYMX
|
-212 M | - | -19.68 % | $ 18.4 M | Canada |
 |
ObsEva SA
OBSV
|
-379 M | - | -15.52 % | $ 10.5 M | Schweiz |
 |
Oncorus
ONCR
|
-272 M | - | -8.54 % | $ 3.19 M | USA |
 |
OncoSec Medical Incorporated
ONCS
|
-286 M | - | 31.87 % | $ 1.61 M | USA |
 |
Oncternal Therapeutics
ONCT
|
-198 M | - | -24.12 % | $ 1.56 M | USA |
 |
Opiant Pharmaceuticals
OPNT
|
-61.7 M | - | - | $ 109 M | USA |
 |
Orchard Therapeutics plc
ORTX
|
-901 M | - | 1.02 % | $ 90.8 M | Britain |